<bill session="107" type="h" number="4832" updated="2013-07-14T18:58:33-04:00">
  <state datetime="2002-05-23">REFERRED</state>
  <status>
    <introduced datetime="2002-05-23"/>
  </status>
  <introduced datetime="2002-05-23"/>
  <titles>
    <title as="introduced" type="short">Prescription Drug Comparative Effectiveness Act of 2002</title>
    <title as="introduced" type="official">To require the Director of the Agency for Healthcare Research and Quality to conduct studies on the comparative effectiveness and cost-effectiveness of prescription drugs that account for high levels of expenditures or use by individuals eligible for Medicare or Medicaid, and for other purposes.</title>
  </titles>
  <sponsor id="400007"/>
  <cosponsors>
    <cosponsor id="400525" joined="2002-05-23"/>
    <cosponsor id="400553" joined="2002-06-06"/>
    <cosponsor id="400026" joined="2002-05-23"/>
    <cosponsor id="400527" joined="2002-06-20"/>
    <cosponsor id="400050" joined="2002-05-23"/>
    <cosponsor id="400103" joined="2002-05-23"/>
    <cosponsor id="400143" joined="2002-06-06"/>
    <cosponsor id="400146" joined="2002-06-06"/>
    <cosponsor id="400211" joined="2002-05-23"/>
    <cosponsor id="400230" joined="2002-05-23"/>
    <cosponsor id="400278" joined="2002-09-18"/>
    <cosponsor id="400295" joined="2002-06-20"/>
    <cosponsor id="400333" joined="2002-05-23"/>
    <cosponsor id="400358" joined="2002-06-06"/>
    <cosponsor id="400378" joined="2002-07-09"/>
    <cosponsor id="400387" joined="2002-05-23"/>
    <cosponsor id="400509" joined="2002-06-20"/>
    <cosponsor id="400407" joined="2002-06-06"/>
    <cosponsor id="400425" joined="2002-05-23"/>
  </cosponsors>
  <actions>
    <action state="REFERRED" datetime="2002-05-23">
      <text>Referred to the House Committee on Energy and Commerce.</text>
    </action>
    <action datetime="2002-06-03">
      <text>Referred to the Subcommittee on Health.</text>
      <committee name="House Committee on Energy and Commerce"/>
    </action>
  </actions>
  <committees>
    <committee code="HSIF" name="House Energy and Commerce" activity="Referral, In Committee"/>
    <committee activity="Referral" code="HSIF14" subcommittee="Health" name="House Energy and Commerce"/>
  </committees>
  <relatedbills/>
  <subjects>
    <term name="Health"/>
    <term name="Clinical trials"/>
    <term name="Congress"/>
    <term name="Congressional reporting requirements"/>
    <term name="Cost effectiveness"/>
    <term name="Drugs"/>
    <term name="Electronic government information"/>
    <term name="Finance and financial sector"/>
    <term name="Government operations and politics"/>
    <term name="Government publicity"/>
    <term name="Internet"/>
    <term name="Medicaid"/>
    <term name="Medicare"/>
    <term name="Pharmaceutical research"/>
    <term name="Science, technology, communications"/>
    <term name="Social welfare"/>
  </subjects>
  <amendments/>
  <summary>5/23/2002--Introduced.
Prescription Drug Comparative Effectiveness Act of 2002 - Directs the Director of the Agency for Healthcare Research and Quality to study, analyze, and report to Congress on valid scientific evidence regarding the comparative effectiveness and cost-effectiveness, relative to other drugs and treatments, of prescription drugs that account for high levels of expenditures or use by individuals entitled to benefits under titles XVIII (Medicare) or XIX (Medicaid) of the Social Security Act.</summary>
</bill>
